Delivery Order SPE2DE24D0013-SPE2D625F2WER
- Not listed
- The U.S. Defense Health Agency, through the Medical Supply Chain, awarded a $40.8K firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 12, 2025, for molecular diagnostic solutions with an ultimate completion date of August 19, 2025. This delivery order, designated 4569068770 and titled XPCOV2/FLU/RSV-10, leverages Cepheid's expertise in infectious disease diagnostics and carries no set-aside designation. The work will be performed at Cepheid's facility in Sunnyvale,...
- The U.S. Defense Department's Medical Supply Chain agency awarded a $40.8K firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28), a Sunnyvale, California-based manufacturer of molecular diagnostic solutions. The award, issued on July 30, 2025, with an ultimate completion date of August 6, 2025, carries no set-aside designation and covers diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. Performance will take place at...
- The U.S. Defense Department's Medical Supply Chain awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28), a Sunnyvale, California-based manufacturer of molecular diagnostic solutions. This delivery order, issued on August 11, 2025, with an ultimate completion date of August 18, 2025, pertains to XPCOV2/FLU/RSV-10 testing capabilities and carries no set-aside designation. The contract represents work performed under Cepheid's larger indefinite delivery vehicles,...
- The U.S. Defense Medical Supply Chain awarded a firm fixed-price delivery order valued at $10,200 to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 15, 2025, with completion scheduled for August 22, 2025. The delivery order, designated 4569128836 for XPCOV2/FLU/RSV-10 diagnostic solutions, carries no set-aside designation and will be performed at Cepheid's Sunnyvale, California facility. This award represents procurement of molecular diagnostic testing capabilities, specifically for detection of...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $5,174.64 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28), a Sunnyvale, California-based manufacturer of molecular diagnostic solutions. This delivery order, designated XPCOV2/FLU/RSV-10, has an ultimate completion date of July 30, 2025, and carries no set-aside designation. The contract references diagnostic testing for COVID-19, influenza, and respiratory syncytial virus (RSV), consistent with...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $17,000 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 19, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus testing. The contract, designated as XPCOV2/FLU/RSV-10, has an ultimate completion date of August 26, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. No small business set-aside was utilized for...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $1,913.79 to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 13, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a continuation of the federal government's ongoing procurement of molecular diagnostic solutions from the Sunnyvale, California-based manufacturer. The contract is structured as a delivery...
- The U.S. Defense Department's Medical Supply Chain agency awarded a $7,700 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28), a Sunnyvale, California-based molecular diagnostics manufacturer, on September 3, 2025, with an ultimate completion date of September 10, 2025. This delivery order, designated as XPRSARS-COV2-10, carries no set-aside designation and represents procurement of diagnostic solutions from Cepheid's established portfolio of molecular testing systems. The...
- The U.S. Defense Department's Medical Supply Chain awarded a $8,160 firm fixed-price delivery order to Cepheid Inc., a molecular diagnostic solutions manufacturer based in Sunnyvale, California, on September 2, 2025. This delivery order, designated 4569302270 for XPCOV2/FLU/RSV-10 testing solutions, is scheduled for completion by September 9, 2025, with work performed at the contractor's Sunnyvale facility. The award carries no small business set-aside designation and represents part of...
- The U.S. Department of Defense's Medical Supply Chain awarded a $13.6K firm fixed-price delivery order to Cepheid Inc. on September 4, 2025, with completion scheduled for September 11, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic testing solutions from the Sunnyvale, California-based manufacturer, likely supporting COVID-19, influenza, and respiratory syncytial virus (RSV) detection capabilities across military healthcare systems. The award carries no...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F2WERDelivery Order
The Defense Department's Medical Supply Chain awarded a $57.8K firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on September 8, 2025, for molecular diagnostic solutions with an ultimate completion date of September 15, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, will be performed in Sunnyvale, California, where Cepheid manufactures its GeneXpert diagnostic systems and associated test kits. This award carries no set-aside designation and represents a continuation of Cepheid's longstanding partnership with federal healthcare agencies to supply diagnostic equipment and reagents. This delivery order is issued under one of Cepheid's existing indefinite delivery vehicles with the Veterans Integrated Service Network 21, a $2.5M firm fixed-price contract focused on polymerase chain reaction (PCR) testing for laboratory microbiology applications. The contract nomenclature indicates the delivery order specifically addresses COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic capabilities—conditions central to federal pandemic preparedness and ongoing infectious disease surveillance efforts. Cepheid's molecular diagnostic technologies serve critical roles across multiple VA facilities, the Defense Health Agency, and the Defense Logistics Agency, supporting both clinical decision-making and public health initiatives across the federal healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $57.8k | 9/8/25 |